Makes technical amendments to the RI life science hub regarding the terms of the directors, advisory committees, powers, disposition of hub assets upon termination, and tax status as a governmental unit which is a separate legal entity from the state.
H5985 makes a series of amendments to the Rhode Island Life Science Hub Act. It revises and expands statutory definitions related to life sciences, updates the composition and governance of the hub’s board of directors, and clarifies the role of the president and chief executive officer as an ex officio board member. The bill also formalizes procedures for board meetings, remote participation, conflict disclosures, committee structure, and the review and approval of certification proposals from life science companies.
The bill further expands the hub’s operational authority. It authorizes the hub to administer an investment fund, make grants, loans, investments, and other funding decisions, support clinical trials, create venture capital funds, and establish nonprofit entities to receive charitable contributions for hub purposes. It also strengthens provisions governing bonds, notes, liens, and the use of hub revenues, while specifying that the hub may enter into long-term contracts, acquire and dispose of property, and collaborate with public and private entities to advance life science initiatives in Rhode Island.
The bill amends Chapter 23-99 of the General Laws by changing the legal structure and powers of the Rhode Island Life Science Hub, a separate public corporation and instrumentality of the state. It adds or revises provisions on board membership, governance, fiduciary controls, investment authority, tax exemption, bond eligibility, and lien perfection, and it makes the hub, its property, and its bonds broadly exempt from state and local taxation. It also retroactively applies the act to September 1, 2023, which may affect actions taken by the hub since that date and confirms the hub’s authority to operate investment and nonprofit vehicles tied to life science development.
The bill appears to have been generally favorable in the House, passing on June 16, 2025 by a wide margin of 66-6. The available materials do not include committee testimony or floor debate, but the strong vote suggests broad support for the hub’s mission to promote life science research, commercialization, and job growth in Rhode Island. The bill’s framing as a set of technical amendments also likely contributed to the positive reception.
The main points of potential contention are the expanded powers and financial structure of the hub, especially its authority to issue bonds, create venture capital funds, establish nonprofits, and receive broad tax exemptions. Those provisions may raise concerns about public accountability, state exposure, and the use of quasi-public financing tools, even though the bill states that the state is not liable for the hub’s debts. Another possible issue is the concentration of governance power in a board dominated by gubernatorial appointees and major institutional stakeholders, though the bill also includes disclosure and recusal requirements to address conflicts of interest.